BackViridian Therapeutics Overview

Viridian Therapeutics Current Cash

Latest current cash for VRDN: $160M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$164.99M
↑ 40.62% YoYΔ $47.66M vs prior year quarter

Peer trimmed avg / median

Loading

Viridian Therapeutics Current Cash History

Loading

Viridian Therapeutics vs. peers: Current Cash Comparison

Loading

Viridian Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Viridian Therapeutics (VRDN) FAQ

As of the most recent data (June 2026), VRDN shows a current cash of $160M. That compares with $120M in the prior-year period — up 40.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, VRDN's current cash is now $160M (was $120M) — a 40.6% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Viridian Therapeutics is outperforming or lagging.

Tracking VRDN's current cash over time shows whether Viridian Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $160M That compares with $120M in the prior-year period — up 40.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Viridian Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $160M) with ownership activity and broader fundamentals.

Viridian Therapeutics's current cash is $160M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.